Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

Triebels, V. H.J.M.; Taphoorn, Martin J.B.; Brandes, Alba Ariela; Menten, Johan; Frénay, M.; Tosoni, Alicia; Kros, Johan M.; Stege, E. Biemond-ter; Enting, Roeline; Allgeier, Anouk; Heuvel, Irene van; Bent, Martin J. van den

doi:10.1212/01.wnl.0000137049.65631.db

Cited by 81 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This probably reflects the importance of patient selection, in particular, concerning "true" oligodendroglioma. Regardless of the sequence of treatment, TMZ first or PCV first, and the other agent used Stupp,Hegi,van den Bent et al 175 www.TheOncologist.com in second-line therapy, the first-line response rate is about 55%-70% and the second-line response rate is 17%-26% [111]. This implies that even patients with chemotherapysensitive oligodendroglioma have a limited sensitivity to second-line treatment, and a further improvement in medical treatment requires novel agents.…”

Section: Treatment Of Recurrent Oligoastrocytoma and Oligodendrogliomamentioning

confidence: 99%

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Stupp

Hegi

Bent³

et al. 2006

The Oncologist

370

241

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. List the different major subtypes of glioma and identify the appropriate treatment strategies for patients with high-grade and low-grade gliomas.2. Discuss the available evidence for the treatment of newly diagnosed glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma.3. Identify approved agents and other active or investigational agents used to treat patients with newly diagnosed and recurrent glioma. shown that early neoadjuvant or adjuvant administration of procarbazine, lomustine, and vincristine chemotherapy prolongs disease-free survival; however, it has no impact on overall survival. Temozolomide, a novel alkylating agent, has shown modest activity against recurrent glioma. In combination with radiotherapy in newly diagnosed patients with glioblastoma, temozolomide significantly prolongs survival. Molecular studies have demonstrated that the benefit is mainly observed Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Section: Treatment Of Recurrent Oligoastrocytoma and Oligodendrogliomamentioning

confidence: 99%

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Stupp

Hegi

Bent³

et al. 2006

The Oncologist

370

241

View full text Add to dashboard Cite

show abstract

“…Second-line PCV after failure with temozolomide induced a response in only 17% of patients, but 50% were still free from progression at 6 months and 21% were still free from progression at 12 months [60]. Similarly, 25% of patients had an objective response to temozolomide after PCV and 29% and 11% of patients were free from progression after 6 and 12 months, respectively [61].…”

Section: Second-line Chemotherapy In Recurrent Aotsmentioning

confidence: 99%

Oligodendrogliomas: Molecular Biology and Treatment

Bromberg

Bent

2009

The Oncologist

View full text Add to dashboard Cite

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. Target audience:Physicians who wish to advance their current knowledge of clinical cancer medicine in neuro-oncology. LEARNING OBJECTIVES1. Evaluate the current challenges in the histological diagnosis of oligodendroglial tumors and apply best practices to optimize patient outcomes.2. Analyze the molecular alterations in different subsets of tumors with oligodendroglial morphology.3. Formulate treatment options for your patients with newly diagnosed and recurrent oligodendroglial tumors.This article is available for continuing medical education credit at CME.TheOncologist.com. The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. CME CME ABSTRACT Neuro-OncologyThe Oncologist

show abstract

“…Pour les oligodendrogliomes anaplasiques avec codélétion 1p-19q, leur grande chimiosensibilité fait proposer une chimiothérapie à la récidive de type PCV ou par témozolomide [44,45,89], en sachant que la tolérance hématologique est meilleure pour ce dernier et qu'il n'y a pas d'étude comparative des deux protocoles.…”

Section: Prise En Charge à La Récidiveunclassified